BioCentury
ARTICLE | Finance

Ebb & Flow

September 11, 2006 7:00 AM UTC

With some SEK1.2 billion ($165.5 million) in cash in its coffers at June 30, Biovitrum is in no rush to raise additional capital as it seeks to list its shares on the Stockholm Stock Exchange. Thus, while its shares are due to be priced this week, the company’s listing plans do not include selling new shares or raising any money.

"Our revenue streams have given us a strong balance sheet and we are able to fund all our R&D from this cash flow. However, when we need to issue new shares to finance future business objectives, this listing will give us ready access to the capital market," CFO Goran Arvidsen told Ebb & Flow. ...